SG Americas Securities
PHAT icon

SG Americas Securities’s Phathom Pharmaceuticals PHAT Stock Holding History

SG Americas Securities’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,497
Closed -$274K – 3586
2025
Q4 		$274K Buy
+16,497
New +$236K ﹤0.01% 2796
2024
Q4 		– Sell
-13,483
Closed -$244K – 3502
2024
Q3 		$244K Buy
+13,483
New +$188K ﹤0.01% 2334
2024
Q2 		– Sell
-18,873
Closed -$200K – 3202
2024
Q1 		$200K Buy
18,873
+803
+4% +$6.82K ﹤0.01% 1974
2023
Q4 		$165K Buy
18,070
+5,906
+49% +$50.9K ﹤0.01% 2339
2023
Q3 		$126K Buy
+12,164
New +$167K ﹤0.01% 2640
2023
Q2 		– Sell
-11,328
Closed -$81K – 2963
2023
Q1 		$81K Buy
+11,328
New +$99.5K ﹤0.01% 2977
2021
Q4 		– Sell
-8,420
Closed -$270K – 3709
2021
Q3 		$270K Buy
+8,420
New +$280K ﹤0.01% 3020
2020
Q3 		– Sell
-5,858
Closed -$193K – 3275
2020
Q2 		$193K Buy
+5,858
New +$225K ﹤0.01% 2888

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

SG Americas Securities's PHAT Position: Q1 2026 in Review

SG Americas Securities sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 16,497 shares — an estimated $274K sold.

SG Americas Securities first reported a position in PHAT in Q2 2020 and held it in 8 quarters. The position peaked at $274K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • SG Americas Securities reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 16,497 Phathom Pharmaceuticals shares in Q1 2026, an estimated $274K.
  • SG Americas Securities first reported a position in Phathom Pharmaceuticals in Q2 2020 and held it in 8 quarters.
  • SG Americas Securities's Phathom Pharmaceuticals position peaked at $274K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.